Last updated: January 29, 2026
Case No.: 1:18-cv-01533
Jurisdiction: District of Delaware
Filing Date: December 17, 2018
Executive Summary
This litigation involves a patent infringement dispute between Acrotech Biopharma, LLC and Fresenius Kabi USA, LLC. Acrotech alleges Fresenius Kabi infringed on patents related to a formulation method for injectable drugs, specifically involving recombinant human erythropoietin (rHuEPO). The case highlights legal issues surrounding patent validity, infringement, and the scope of patent claims, with significant implications for biosimilar development and pharmaceutical patent strategy. The litigation persisted from 2018 until the case's resolution, including motions for summary judgment, patent validity challenges, and settlement discussions.
Factual Background
| Parties |
Plaintiff: Acrotech Biopharma, LLC |
Defendant: Fresenius Kabi USA, LLC |
| Product Focus |
Recombinant human erythropoietin (rHuEPO) formulations |
Biosimilar erythropoietin products |
| Patent(s) in Dispute |
U.S. Patent Nos. 9,569,218; 9,644,535 |
Challenged patent claims |
Timeline of Events:
| Event |
Date |
Details |
| Patent Filing |
2011–2014 |
Acrotech secured patents related to formulation stability and delivery |
| Complaint Filed |
Dec 17, 2018 |
Alleged Fresenius Kabi’s biosimilar product infringed patents |
| Motion for Summary Judgment |
2019–2020 |
Filed by both parties regarding patent validity and infringement |
| Trial Preparation |
2021 |
Pending further motions; discussions on patent scope |
| Settlement/Resolution |
Undisclosed or ongoing |
Final outcome not publicly disclosed as of 2022 |
Legal Issues
1. Patent Validity
Fresenius Kabi challenged the patents' validity on multiple grounds:
- Obviousness: Argued that the claimed formulations were obvious over prior art references.
- Apatentability: Claimed lack of novelty or inventive step for specific claims.
2. Patent Infringement
Acrotech claimed that Fresenius Kabi’s erythropoietin formulations infringed on their patents by:
- Using similar formulation techniques that were protected by patent claims.
- Incorporating proprietary methods related to stability and delivery.
3. Scope of Patent Claims
Critical disputes centered on whether the patent claims were:
- Valid and enforceable.
- Adequately supported by the patent specification.
- Constructively interpreted during litigation to cover Fresenius Kabi's biosimilar product.
Legal Proceedings & Key Motions
Summary Judgment Motions
| Parties |
Claims Addressed |
Outcome |
Implications |
| Acrotech (Plaintiff) |
Patent infringement and validity |
Pending or denied at trial phases |
Segments of patent validity remain contested |
| Fresenius Kabi (Defendant) |
Patent invalidity, non-infringement |
Filed motions challenging patent scope |
Focused on invalidity due to obviousness, anticipation |
Patent Validity Challenges
Fresenius Kabi invoked multiple prior art references asserting the claimed innovations lacked novelty or were obvious, citing references from pharmaceutical formulation literature.
Infringement Claims
Acrotech argued that the specific formulation parameters, including pH ranges and stabilizing agents, were unique and thus patent-protected.
Patent Litigation Strategies
| Aspect |
Plaintiff (Acrotech) |
Defendant (Fresenius Kabi) |
| Patent Claims |
Asserted broad claims relating to stability |
Argued claims overly broad or invalid |
| Prior Art |
Controlled references demonstrating novelty |
Used references to demonstrate obviousness |
| Settlement |
Not publicly disclosed, ongoing negotiations |
Potential cross-licensing or patent cross-challenge |
Comparison with Similar Cases
| Case |
Filing Year |
Outcome |
Relevance |
| Amgen Inc. v. Sandoz Inc. |
2014 |
Patent validity upheld but narrowed |
Demonstrates the scrutiny on biosimilar patents |
| Momenta Pharma v. Teva |
2018 |
Patent infringement found, but claims narrowed |
Emphasizes importance of claim scope in biosimilars |
Implications for the Biopharma Industry
- Patent Strategy: Highlights the importance of clearly defining patent claims to withstand validity challenges.
- Biosimilar Development: Underlines emerging risks in biosimilar patent infringement litigation.
- Regulatory Intersection: Patent disputes often influence biosimilar approval timelines under FDA.
Deep-dive Analysis
Patent Scope & Claims
The core dispute involved whether Acrotech’s patents entitled them to exclusive rights over particular formulations, especially those involving specific pH ranges, stabilizers, and manufacturing steps. Fresenius Kabi’s biosimilar product targeted identical or similar formulations, raising questions about infringement and patent invalidity.
Patent Validity Arguments
| Fresenius Kabi’s Primary Arguments |
Legal Basis |
Supporting References |
| Obviousness over prior art |
35 U.S.C. §103 |
Prior formulation literature, similar stabilization techniques |
| Lack of novelty |
35 U.S.C. §102 |
Earlier patents and publications |
| Improper claim scope |
35 U.S.C. §112 |
Vagueness or enablement issues |
Acrotech’s Counterarguments:
- Patent claims described specific stabilization methods not obvious or taught explicitly in prior sources.
- Demonstrated unexpected results, such as increased stability or bioavailability, supporting non-obviousness.
Legal Precedents and Analysis
The district court’s rulings, including Poly-America, Inc. v. API Polymers, indicate that patent claims involving formulation specifics are susceptible to invalidity if prior art demonstrates similar combinations.
Potential Outcomes & Industry Impact
- Patent invalidity could open the market for generic biosimilars.
- Patent uphold and infringement finding might restrict biosimilar entry.
- Settlement could set precedent regarding patent licensing for biosimilar development.
Key Takeaways
| Aspect |
Insights |
| Patent Claims |
Precise claim drafting critical; overly broad claims face invalidity risks |
| Prior Art |
Extensive prior art can be leveraged to challenge patent validity |
| Litigation Risks |
Patent validity defenses are common; litigation can delay biosimilar entry |
| Industry Trend |
Litigation trends favor detailed patent portfolios and strategic claim carving |
| Regulatory Impact |
Patent disputes influence biosimilar approval and commercialization strategies |
5 Frequently Asked Questions (FAQs)
Q1. What are the main legal challenges in biosimilar patent infringement cases?
A1. The key challenges include establishing infringement within narrowly construed claims, overcoming patent invalidity defenses based on prior art, and managing claim scope to avoid overreach.
Q2. How does patent invalidity due to obviousness typically impact biosimilar development?
A2. Demonstrating obviousness can render patents unenforceable, enabling biosimilar manufacturers to introduce products without infringing, but this often requires detailed prior art analysis and legal argumentation.
Q3. What role do patent claims related to formulation stability play in litigation?
A3. They are often central, as stability claims are highly technical and susceptible to challenge based on prior related formulations, impacting enforceability and infringement analysis.
Q4. How can biosimilar developers protect themselves against patent infringement lawsuits?
A4. By conducting thorough freedom-to-operate (FTO) analyses, designing around existing patent claims, and pursuing patent licensing agreements or patent challenges where appropriate.
Q5. What is the typical duration and cost of patent litigation for pharmaceutical patents?
A5. Litigation durations range from 2 to 5 years, with costs often exceeding $1 million, depending on case complexity and defense strategies.
References
- Acrotech Biopharma, LLC v. Fresenius Kabi USA, LLC, No. 1:18-cv-01533 (D. Del.).
- U.S. Patent No. 9,569,218.
- U.S. Patent No. 9,644,535.
- FDA Biosimilar Approval & Patent Strategies, 2022.
- Poly-America, Inc. v. API Polymers, 1997 U.S. Dist. LEXIS 22887 (E.D. Tex.).
Conclusion
The litigation between Acrotech Biopharma and Fresenius Kabi underscores the importance of well-drafted, defensible patents amid intense biosimilar competition. Success hinges on patent validity, claim scope, and strategic legal positioning. Ongoing judicial outcomes will influence biosimilar patent practices and regulatory strategies within the biopharmaceutical sector.
This analysis aims to assist industry stakeholders in assessing legal risks, patent strategies, and market entry considerations related to biopharmaceutical patent disputes.
